Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases at an Australian centre.

ABSTRACT:

Introduction

Gastric cancer is a major cause of cancer mortality, with poorer prognosis in the presence of peritoneal metastases as low as 2.8-9 months. Systemic therapy has a limited role. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been shown to improve survival. This study evaluates survival of patients with gastric cancer and peritoneal metastases (GCPM) undergoing CRS and HIPEC at an Australian centre.

Methods

A retrospective analysis was conducted on a prospectively collected database of patients who underwent CRS and HIPEC for GCPM from January 2009 to December 2023. Data included demographics, perioperative factors, histopathology and survival.

Results

Twenty-four patients were identified, with median postoperative ov

SUBMITTER: Hayler R 

PROVIDER: S-EPMC11921698 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature